Lundbeck to Establish Global Innovation Hub and Relocate US Headquarters to Greater Boston
Danish pharmaceutical company H. Lundbeck A/S will move its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, establishing a global innovation hub. The move aims to leverage the region's life sciences ecosystem and strengthen the company's focus on neuroscience.
H. Lundbeck A/S, a Danish biopharmaceutical company, announced it will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts. The company will establish a global innovation hub in the area, aiming to tap into one of the world's leading life sciences ecosystems.
The relocation is part of Lundbeck's ongoing investment in the US market and supports the next phase of its Focused Innovator strategy. The company seeks to scale its neuroscience portfolio and expand its digital and artificial intelligence capabilities. The transition is expected to take place over the next year.
Charl van Zyl, President and CEO of Lundbeck, stated that the US is a key driver of the company's commercial progress and future growth. "Our investment in Greater Boston is an important step in positioning Lundbeck to capture those opportunities and bring innovative treatments to more people living with brain diseases," he said.
Greater Boston offers a concentration of academic institutions, healthcare organizations, biotech firms, and scientific talent, which Lundbeck aims to integrate with its own expertise. The move builds upon Lundbeck's existing presence in Cambridge, Massachusetts.
Lundbeck emphasized its commitment to retaining its US workforce and ensuring business continuity throughout the transition period. The company stated that its products continue to be available to patients and partners without disruption.